Translational Development Acquisition Corp.

Translational Development Acquisition Corp., whose warrants trade under the ticker TDACW, is a blank-check company targeting the life sciences and biotechnology sector — a focus telegraphed by the firm's name, which references the process of moving scientific discoveries from laboratory research into clinical practice. The company filed a Form 425 communication with the SEC on June 23, 2026, a filing type required of parties to a pending business combination when making regulated public disclosures related to a proposed transaction. The submission adds to the vehicle's active regulatory record as its deal process advances. Sign up for full data on SpacDesk to access complete sponsor information, IPO history, and filing analytics for this and every tracked SPAC.